STOCK TITAN

Gilead Sciences Inc - GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company focused on developing innovative therapies for life-threatening diseases. This page provides investors and healthcare professionals with timely updates on the company's latest developments, regulatory milestones, and strategic initiatives.

Access comprehensive coverage of Gilead's press releases and news, including updates on antiviral therapies, oncology research, and clinical trial results. Our curated collection features earnings announcements, partnership details, and progress reports on treatments for HIV, hepatitis, and emerging cancer therapies.

Stay informed about critical developments through verified updates on FDA approvals, research collaborations, and therapeutic advancements. All content is organized chronologically for quick reference, with clear sourcing to ensure transparency.

Bookmark this page for streamlined access to Gilead Sciences' official communications and third-party analysis. Regularly updated to reflect the company's evolving pipeline and market position, this resource supports informed decision-making for stakeholders at all levels.

Rhea-AI Summary

Kite, a Gilead Company (Nasdaq: GILD), has appointed Frank Neumann, MD, PhD, as Senior Vice President and Global Head of Clinical Development. Dr. Neumann will spearhead Kite's clinical initiatives in hematological malignancies and solid tumors. He joins from Verastem, bringing extensive experience in cell therapy and oncology. Ken Takeshita, MD, is set to leave the company at the end of February after successfully overseeing multiple clinical program milestones, including FDA approvals. Dr. Neumann is excited to expand Kite's cell therapy portfolio, aiming to deliver innovative treatments for cancer patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.72%
Tags
management clinical trial
-
Rhea-AI Summary

Gilead Sciences (Nasdaq: GILD) has announced a 4.4% increase in its quarterly cash dividend, raising it to $0.71 per share. This adjustment will take effect in the first quarter of 2021, with the dividend payable on March 30, 2021, to stockholders on record as of March 15, 2021. The decision reflects Gilead's ongoing commitment to returning value to shareholders, although future dividends will remain subject to approval by the Board of Directors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
dividends
-
Rhea-AI Summary

Gilead Sciences (Nasdaq: GILD) announced its Q4 and full-year 2020 results, emphasizing the significant role of Veklury in treating hospitalized COVID-19 patients. CEO Daniel O’Day highlighted the company's commitment to addressing various health needs, including HIV and cancer. Gilead is optimistic about growth opportunities in oncology with Trodelvy, while continuing its leadership in antivirals. Overall, the company is positioned for growth as it enters 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
none
-
Rhea-AI Summary

Gilead Sciences (Nasdaq: GILD) and Gritstone Oncology (Nasdaq: GRTS) have announced a collaboration to develop a vaccine-based immunotherapy aimed at curing human immunodeficiency virus (HIV) infection. The partnership will utilize Gritstone's prime-boost vaccine platform, combining self-amplifying mRNA and adenoviral vectors with antigens from Gilead. Gilead will initially invest $60 million, including a $30 million cash payment and a $30 million equity investment, and has the option for further funding up to $725 million based on clinical milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
Rhea-AI Summary

Gilead Sciences, Inc. (Nasdaq: GILD) is set to announce its fourth quarter and full year 2020 financial results on February 4, following market close. A conference call with management will occur at 4:30 p.m. ET to discuss the results and provide a business update. Investors can access the live webcast on the company’s Investors page. Additionally, a replay will be available approximately two hours after the call until February 6. Gilead is dedicated to developing innovative medicines for serious health challenges globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.06%
Tags
Rhea-AI Summary

Kite, a Gilead Company (Nasdaq: GILD), announced the appointment of Dr. Francesco Marincola as Senior Vice President and Global Head of Cell Therapy Research, effective February 1. Dr. Marincola brings extensive experience in oncology and immunotherapy, previously serving as President and Chief Scientific Officer at Refuge Biotechnologies Inc. His leadership is expected to enhance Kite’s research in CAR T therapies. Kite focuses on innovative cancer immunotherapies, aiming to provide curative cell therapies for patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.91%
Tags
none
-
Rhea-AI Summary

Gilead Sciences (NASDAQ: GILD) and Vir Biotechnology (NASDAQ: VIR) announced a clinical collaboration to explore new therapeutic combinations for chronic hepatitis B virus (HBV). A Phase 2 trial will evaluate therapies involving Gilead's selgantolimod, VIR's VIR-2218, and a PD-1 antagonist. The study aims to achieve a functional cure, defined by the loss of hepatitis B surface antigen (HBsAg) and HBV DNA. Both firms retain rights to their products and will consider future studies based on Phase 2 results. Current therapies require lifelong treatment for over 290 million HBV patients globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
Rhea-AI Summary

Gilead Sciences has revised its full-year 2020 guidance, now projecting product sales between $24.30 billion and $24.35 billion, an increase attributed to higher demand for Veklury due to COVID-19. Non-GAAP diluted EPS is forecasted at $6.98 to $7.08, while GAAP diluted EPS is expected to be between ($0.08) and $0.02. R&D expenses are estimated to grow by around 20%, while SG&A expenses are projected to rise by 10%. The company will discuss results in a conference call following its J.P. Morgan Healthcare Conference on January 11, 2021.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.84%
Tags
none
Rhea-AI Summary

Kite, a Gilead Company (Nasdaq: GILD), has partnered with Oxford BioTherapeutics Ltd. to explore five novel oncology targets for hematologic and solid tumors. OBT will validate these targets using its OGAP® discovery platform and create antibodies, with Kite and Gilead securing exclusive rights for development and commercialization. The partnership involves an upfront payment and potential future milestone payments and royalties. Executives from both companies emphasize the collaboration's potential to enhance cancer therapy outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
none
Gilead Sciences Inc

Nasdaq:GILD

GILD Rankings

GILD Stock Data

130.32B
1.24B
0.11%
89.78%
1.81%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States
FOSTER CITY